9 Result(s)

Article

Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines offer the potential for protection ...

H. Parry, G. McIlroy, R. Bruton, M. Ali, C. Stephens, S. Damery… in Blood Cancer Journal (2021)

Article

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

In the phase 3 RESONATE study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patient...

J R Brown, P Hillmen, S O’Brien, J C Barrientos, N M Reddy, S E Coutre, C S Tam… in Leukemia (2018)

Article

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL

ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontline therapy in fit patients is fludarabine,...

D R Howard, T Munir, L McParland, A C Rawstron, D Milligan, A Schuh, A Hockaday… in Leukemia (2017)

Article

Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL

ADMIRE was a multicenter, randomized-controlled, open, phase IIB superiority trial in previously untreated chronic lymphocytic leukemia. Conventional front-line therapy in fit patients is fludarabine, cyclopho...

T Munir, D R Howard, L McParland, C Pocock, A C Rawstron, A Hockaday… in Leukemia (2017)

Article

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

M Montillo, S O'Brien, A Tedeschi, J C Byrd, C Dearden, D Gill… in Blood Cancer Journal (2017)

Article

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia

Histone methyltransferases (HMTs) are important epigenetic regulators of gene transcription and are disrupted at the genomic level in a spectrum of human tumours including haematological malignancies. Using hi...

H Parker, M J J Rose-Zerilli, M Larrayoz, R Clifford, J Edelmann, S Blakemore… in Leukemia (2016)

Article

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy,...

A C Rawstron, C Fazi, A Agathangelidis, N Villamor, R Letestu, J Nomdedeu… in Leukemia (2016)

Article

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial

Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytog...

A Bühler, C-M Wendtner, T J Kipps, L Rassenti, G A M Fraser… in Blood Cancer Journal (2016)

Article

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia

The naturally occurring oncolytic virus (OV), reovirus, replicates in cancer cells causing direct cytotoxicity, and can activate innate and adaptive immune responses to facilitate tumour clearance. Reovirus is...

C Parrish, G B Scott, G Migneco, K J Scott, L P Steele, E Ilett, E J West… in Leukemia (2015)